Alzheimer’s disease, a brain disorder that affects memory and thinking skills, is the most common type of dementia, according to the National Institutes of Health. “A blood test being negative speeds up the investigation for other causes of the symptoms and this is just as important,” Ashton said. Isaacson, who has researched blood biomarkers in people with no or minimal cognitive complaints, likened testing blood samples for signs of Alzheimer’s disease to how people undergo routine blood tests for high cholesterol. It is possible that currently available treatments for Alzheimer’s disease would work better in those diagnosed early in this way,” he said. The combination of a simple screening test with an effective treatment for Alzheimer’s disease would have a dramatic impact for individuals and for society.”

---

Persons: ” Nicholas Ashton, Ashton, ”, Kaj Blennow, Henrik Zetterberg, antiamyloid, immunoassay, ” Ashton, Richard Isaacson, ” Isaacson, Isaacson, ‘, “, Dr, Sanjay Gupta, David Curtis, ” Curtis Organizations: CNN, University of Gothenburg, National Institutes of Health, Quest Diagnostics, Alzheimer’s, Alzheimer’s Association, Get CNN, CNN Health, University College London, Science Media Locations: Sweden, United States, Wisconsin, Pau, Florida